Therycell GmbH

- founded as a privately held company in December 2017 as spin-out of HSDiagnomics GmbH

- focus: development of an innovative, individual cancer therapy based on autologous T-Lympocytes

- 2 existing patents:

a) the TCRsafe-method which allows high-throughput profiling of tens of thousands T-Lymphocytes by NGS and

b) Identification of tumor reactive T-cell clonotypes by comparative sequencing of patient tumor samples

- Therycell’s method works without any a-priori knowledge of the respective tumor antigens or other tumor markers

- current targets are lung, pancreas and breast cancer